Vervloet D, van der Brempt X, Charpin D, Birnbaum J
Département des Maladies Respiratoires, Hôpital Sainte-Marguerite, Marseille, France.
Lung. 1990;168 Suppl:1013-24. doi: 10.1007/BF02718239.
Much more work is needed to specify the correct indications for immunotherapy in respiratory allergic diseases. Immunotherapy with pollen and mite extracts has shown some clinical efficacy versus placebo in controlled studies in allergic rhinitis and/or asthma. However, controlled studies comparing the cost, the risk factors and the efficacy of immunotherapy versus treatment with antihistaminic drugs, bronchodilators and topical steroids are needed. Additional studies are needed to established the place of immunotherapy in animal danders and mould allergy. In any case, before initiating immunotherapy in respiratory allergy the following questions must be answered: is there sufficient evidence of a close relationship between symptoms and allergen exposure? is it possible to achieve efficient allergen avoidance? is simple drug treatment no sufficient? is there evidence in the literature of effectiveness of IT for this allergen? is the patient able to comply with a long and constraining treatment?
要明确免疫疗法在呼吸道过敏性疾病中的正确适应症,还需要开展更多工作。在变应性鼻炎和/或哮喘的对照研究中,花粉和螨提取物免疫疗法与安慰剂相比已显示出一定的临床疗效。然而,需要开展对照研究来比较免疫疗法与抗组胺药、支气管扩张剂和局部类固醇治疗的成本、风险因素及疗效。还需要进一步研究以确定免疫疗法在动物皮屑和霉菌过敏中的地位。无论如何,在开始呼吸道过敏的免疫疗法之前,必须回答以下问题:症状与过敏原暴露之间是否存在密切关系的充分证据?是否有可能有效避免接触过敏原?单纯药物治疗是否不够?文献中是否有关于该过敏原免疫疗法有效性的证据?患者是否能够依从长期且受限的治疗?